Skip to content

Dossier · COCO · Dormant

COCO · The Vita Coco Company, Inc. · Stock research

Last analysed ·

Current thesis

Coconut-water category leader re-rated ~+130% off the $31.79 low on a real Q1 FY26 blowout, but that catalyst is now ~10 weeks stale and the swing-momentum signal round-tripped (bought 6/3, sold 6/18). The 2026-07-09 Piper PT raise landed at only $74 — below the $79.70 ATH so sell-side is clustering near fair value, not chasing. Q2 FY26 (~2026-07-29) is now the in-window binary; the edge is a base or the print reaction, not a chase near the high.

Invalidation trigger

A weekly close below $60 fills the late-April Q1 breakaway gap and negates the full re-rate (completed round-trip). Secondary: a Q2 print ~2026-07-29 with net sales below ~$185M signals deceleration in the seasonally strongest quarter and flips the theme toward SATURATED.

Thesis status

Open commitment catalyst in 10dscored if the trigger above fires How this is scored →

Latest analysis and events for COCO —

As of 2026-07-12, orbyd's latest analysis for The Vita Coco Company, Inc. (COCO): Coconut-water category leader re-rated ~+130% off the $31.79 low on a real Q1 FY26 blowout, but that catalyst is now ~10 weeks stale and the swing-momentum signal round-tripped (bought 6/3, sold 6/18). The 2026-07-09 Piper PT raise landed at only $74 — below the $79.70 ATH so sell-side is clustering near fair value, not chasing. Q2 FY26 (~2026-07-29) is now the in-window binary; the edge is a base or the print reaction, not a chase near the high.

Invalidation trigger: A weekly close below $60 fills the late-April Q1 breakaway gap and negates the full re-rate (completed round-trip). Secondary: a Q2 print ~2026-07-29 with net sales below ~$185M signals deceleration in the seasonally strongest quarter and flips the theme toward SATURATED.

Next dated event on file: — catalyst in 10d.

Current Thesis

The narrative leg an investor bought here was a category-leader re-rate: coconut water went from niche to GLP-1-era hydration staple, and Q1 FY26 (reported late April 2026) put hard numbers on it net sales +37% YoY to $179.8M, EPS $0.50 vs $0.32 est, FY guide raised. Price ran ~+130% off the $31.79 low into a $79.70 ATH by 2026-05-18. That accelerant is now roughly ten weeks stale, and the momentum tape has cooled: the IBD SwingTrader signal that bought on 2026-06-03 sold on 2026-06-18, a full round-trip in fifteen days. The freshest read is the 2026-07-09 Piper Sandler note Overweight reiterated but the price target raised only to $74, below both Wells Fargo's $85 Street-high and the $79.70 ATH. Sell-side is now clustering near current levels rather than chasing, which is what a maturing narrative looks like. The one item that changes the clock: the Q2 FY26 print, estimated ~2026-07-29, has moved inside the 30-day window. The edge is a base into that print or a reaction to it, not a chase near the high with a fresh 52x-plus multiple.

Bullish and bearish views on The Vita Coco Company, Inc.

The model's bull view on The Vita Coco Company, Inc. (COCO), in brief: Q1 FY26 (late April 2026): net sales $179.8M, +37% YoY, roughly 22% above the ~$147M consensus; Vita Coco Coconut Water itself +42%. The bear view: 2026-07-09 Piper PT of $74 sits below the $79.70 ATH. Both cases follow in full.

Bull Case

  • Q1 FY26 (late April 2026): net sales $179.8M, +37% YoY, roughly 22% above the ~$147M consensus; Vita Coco Coconut Water itself +42%. Demand- and volume-led, not a multiple story.
  • EPS $0.50 vs $0.32 est (+56% surprise); Adj EBITDA $38.7M; gross margin ~40% on pricing plus lower ocean freight operating leverage flowed to the bottom line.
  • FY26 guide raised (late April 2026) to net sales $720–735M / Adj EBITDA $132–138M management pressed the beat rather than sandbagging.
  • Piper Sandler reiterated Overweight, PT to $74 on 2026-07-09 the second money-center desk to endorse the story; incremental sell-side coverage still building even if the target is conservative.
  • Wells Fargo Overweight, Street-high PT $85 (2026-05-18) the bull anchor remains ~15% above the Piper mark.
  • Secular hydration tailwind: low-sugar, GLP-1-adjacent positioning with Vita Coco the dominant US coconut-water brand (~50%+ share), effectively owning the category narrative into the seasonally strongest summer quarter.

Bear Case

  • 2026-07-09 Piper PT of $74 sits below the $79.70 ATH. A price-target raise that lands under the prior high and near spot is the sell-side converging on fair value a maturing-narrative marker, not fuel.
  • 2026-06-18: IBD SwingTrader sold the same name it bought on 2026-06-03. The swing-momentum setup that fed the early-June bounce has already unwound.
  • ~+130% off the low at ~54x trailing earnings on a coconut-water company. A premium multiple holds only while the accelerant is live, and the Q1 accelerant fired in late April.
  • 2026-05-15 Benzinga overbought flag tagged COCO a defensive name with RSI>70 that "may plunge." It kept running then; the 6/18 sell signal has since validated the warning.
  • First lower high of the run is on the tape the digestion under the 5/18 ATH is consolidation without a new breakout.
  • Margin help is cyclical. The ~40% gross margin leaned on lower ocean freight, a swing factor that can reverse as fast as it helped.
  • Single name, not a cluster. No tight peer group breaking out in sympathy; the internal theme tag churned repeatedly, signalling low conviction in the categorization itself.

Setup & Price Structure

  • 52-wk range $31.79–$79.70; ATH close $79.23 (2026-05-18); mkt cap ~$4.19B; ~54x P/E.
  • The late-April print gapped price from ~$60 into the high-$70s; the peak printed $79.70 on 5/18, then the name digested in a $73–75 shelf just beneath the high through early June post-catalyst consolidation, not a fresh pivot break.
  • Estimated moving averages: rising 20-EMA tracking ~$72–74; 50-day rising into ~$66–68; the post-earnings breakaway-gap base sits ~$60 and is the structural line for the entire re-rate.
  • A pullback that holds the rising 20-EMA and turns up would be the cleaner momentum re-entry; a chase into the print near the ATH carries binary risk with limited analyst headroom (Piper $74, WF $85).

Catalyst Calendar (next 30 days)

  • ~2026-07-24 (est.): earnings blackout window opens, ~3 trading days ahead of the Q2 print binary risk builds, fresh entries into the print carry gap risk in both directions.
  • ~2026-07-29 (est.): Q2 FY26 report. Watch net sales vs ~$185M (seasonally strongest quarter), coconut-water volume growth vs Q1's +42%, gross-margin durability as freight normalizes, and any FY26 guide revision off the $720–735M sales / $132–138M EBITDA framework.

Elapsed catalysts

  • Rolling: additional sell-side PT revisions post-Piper (2026-07-09) a cluster of raises toward/through $85 would signal re-acceleration; more targets landing near spot confirm saturation. _(passed 10d ago)_

What Would Change Our Mind

  • Downside: a weekly close below $60 fills the late-April breakaway gap and negates the full re-rate at that point the story is a completed round-trip. A Q2 print ~2026-07-29 with net sales below ~$185M would flag deceleration in the strongest quarter and pull the narrative toward SATURATED.
  • Upside re-accelerant: a weekly close above the $79.70 ATH on expanding volume, or a Q2 beat that raises FY guide again, would re-open the trend and justify sizing on the next higher-low retest rather than at the high.

Correlation Notes

COCO trades as an idiosyncratic single-name story rather than a basket member there is no tight coconut-water peer group to confirm a regime. Loose reads come from functional-beverage and hydration names (energy/better-for-you beverage complex) and, more broadly, the consumer-discretionary-versus-staples rotation, where a defensive-tilt bid supported the spring run. The GLP-1/low-sugar hydration theme is the durable macro backdrop; a rotation out of higher-multiple consumer names on rate or macro stress would pressure the multiple independent of Vita Coco's own numbers. Absent a cluster, the tape here keys off company-specific catalysts the Q2 print above all.

Notes

  • DORMANT → active watch as of 2026-06-04 refresh.
  • Q1 FY26 (reported late April 2026): net sales $179.8M +37% YoY, EPS $0.50 vs $0.32 est, Adj EBITDA $38.7M, gross margin ~40%, coconut water +42%. FY26 guide raised to $720-735M sales / $132-138M EBITDA.
  • Next earnings ~2026-07-29 (Q2 FY26) OUTSIDE 30d window; the timing gap is the core reason this is not a fresh fat pitch.
  • Wells Fargo Overweight, Street-high PT $85 (2026-05-18). IBD SwingTrader buy signal 2026-06-03.
  • ATH close $79.23 on 2026-05-18; 52wk range $31.79-$79.70; ~54x P/E; mkt cap ~$4.19B.
  • Stance at ~$74: avoid for 20-EMA pullback (valid for MATURING theme) or LOW probe do NOT chase ATH. Earnings blackout ~3 trading days before 7/29.
  • 5/15 Benzinga flagged COCO overbought (RSI>70) defensive name 'may plunge' saturation warning on board though it kept running.
  • DORMANT → active watch. Fresh entry at ~$74 near ATH with no catalyst for ~8 weeks = chase, not a fat pitch; edge is the 20-EMA pullback or pre-7/29 ramp.
  • Next earnings ~2026-07-29 (Q2 FY26) OUTSIDE 30d window. Earnings blackout ~3 trading days before. The timing gap is the core reason this is not a fresh fat pitch.
  • ATH close $79.23 on 2026-05-18; 52wk range $31.79-$79.70; ~54x P/E; mkt cap ~$4.19B; spot ~$74 (2026-06-03).
  • 5/15 Benzinga flagged COCO overbought (RSI>70) defensive name 'may plunge' saturation warning on the board though it kept running.
  • Single name, not a cluster theme no tight peer group confirming a regime; theme tag churned ~6× in 11 days.
  • 2026-06-18 Benzinga: IBD SwingTrader SOLD COCO reversal of its 2026-06-03 buy signal within 15 days; momentum-flow signal now negative, validating the prior overbought warning.
  • Next earnings ~2026-07-29 (Q2 FY26) OUTSIDE the 30d window. Earnings blackout ~3 trading days before. The timing gap is the core reason this is not a fresh fat pitch.
  • Wells Fargo Overweight, Street-high PT $85 (2026-05-18). ATH close $79.23 on 2026-05-18; 52wk range $31.79-$79.70; ~54x P/E; mkt cap ~$4.19B.
  • Stance near the high: avoid fresh entries with no catalyst for ~6 weeks; the only edge is a 20-EMA pullback (~$72-74) holding with a higher-low, or a pre-7/29 ramp. Do NOT chase the ATH.
  • Single name, not a cluster theme no tight peer group confirming a regime; theme tag churned ~6x in 11 days. CELH is the closest functional-beverage momentum analog for sympathy reads.
  • 5/15 Benzinga flagged COCO overbought (RSI>70) defensive name 'may plunge' saturation warning that the 6/18 SwingTrader exit has now started to confirm.
  • Q2 FY26 print estimated ~2026-07-29 now INSIDE the 30d window (17 days out as of 2026-07-12). Earnings blackout ~3 trading days before (~7/24); avoid fresh entries into the print (binary gap risk).
  • 2026-07-09 Piper Sandler reiterated Overweight, PT raised to only $74 — below Wells Fargo Street-high $85 (2026-05-18) and below the $79.70 ATH. Targets clustering near spot = maturing narrative, not acceleration.
  • Momentum cooled: IBD SwingTrader bought 2026-06-03, sold 2026-06-18 (15-day round-trip). 2026-05-15 Benzinga overbought (RSI>70) warning since validated.
  • ATH close $79.23 on 2026-05-18; 52wk range $31.79-$79.70; ~54x P/E; mkt cap ~$4.19B. Est levels: 20-EMA ~$72-74, 50-day ~$66-68, breakaway-gap base ~$60.
  • Single name, not a cluster theme no tight peer group confirming a regime; internal theme tag churned repeatedly. Edge is a 20-EMA pullback or the Q2 print reaction, not a chase near the high.

Related · shared themes

MTUM

The AI-memory leg MTUM rotated into at the May reconstitution has rolled over: SOX -20%+ from its June peak, memory names in a bear market, and the fund closed $302.09 on 2026-07-17, below the $310 shelf that defined the post-reconstitution base. With ~36% in the semi complex and no rebalance until November, this is a falling-knife AI-hardware proxy with a lagged exit.

LOW

WEST

Westrock Coffee Company

Conway extract/RTD platform inflecting capex to cash: Q1 (5/07) beat revenue with record adjusted EBITDA, FCF-positive-H2 guide reaffirmed, and a 6/30 debt-maturity extension cleared the near-term refi wall. Stock re-rated ~the published invalidation level→$9.50 near the $9.81 high on PT hikes real and accelerating, but a fresh entry above the ~$8.88 average PT into an ~8-week gap to Q2 (~8/6) is extended.

LOW

ALGT

Allegiant Travel Company

A three-week sell-side upgrade cascade (Goldman $125→$142, JPM initiates OW $156, Citi/Melius Buy $156–$160, Barclays OW $145) plus a fuel-cost tailwind as the Hormuz crude spike unwinds has re-rated Allegiant's post-Sunseeker ULCC turnaround. Theme is accelerating with the whole airline complex (JETS at pre-Covid highs), but the move has more than doubled off the low into a seasonally soft Q2 print on ~2026-08-03.

HIGH

AFRM

Affirm Holdings, Inc.

Q3 FY26 killed the credit-stress bear case (GMV +35%, first GAAP operating profit, clean delinquency), and a July sell-side cluster six PT raises/initiations to $96–$117 in ten days is accelerating the re-rate off the mid-June 200-day reclaim (~$74). Momentum confirms, but the move is stretched into a maturing analyst pile-in near the prior $100 high, with no company catalyst until the ~mid-August print.

MEDIUM

See also · stocks to watch